Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07628049 · ClinicalTrials.gov registry record · Phase 1
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1,808
- Enrollment target
NCT07628049: Recruiting Phase 1 study, sponsored by GlaxoSmithKline.
NCT07628049 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,808 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2913% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07628049, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,808 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
Primary Outcome
Solicited administration site events include pain, redness (erythema) and swelling at administration site.
Interventions
- BIOLOGICAL RSV/hMPV_V low dose vaccine
- BIOLOGICAL RSV/hMPV_V medium dose vaccine
- BIOLOGICAL RSV/hMPV_V high dose vaccine
- BIOLOGICAL RSV/hMPV_W low dose vaccine
- BIOLOGICAL RSV/hMPV_W medium dose vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,808 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2029-04-05 |
| Phase | Phase 1 |
What NCT07628049 shows while recruiting
NCT07628049 is an interventional study that assigns participants to a tested intervention. Its 1,808 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2913% higher).
The record links to 0 conditions, and to 5 interventions - of which RSV/hMPV_V low dose vaccine is the first listed.
NCT07628049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07628049 about?
NCT07628049 is a clinical study titled "A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults". The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
What is the current status of trial NCT07628049?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,808 participants. The study started on 2026-06-05. Estimated completion is 2029-04-05.
What interventions are being tested in trial NCT07628049?
The interventions under investigation include: RSV/hMPV_V low dose vaccine (BIOLOGICAL), RSV/hMPV_V medium dose vaccine (BIOLOGICAL), RSV/hMPV_V high dose vaccine (BIOLOGICAL), RSV/hMPV_W low dose vaccine (BIOLOGICAL), RSV/hMPV_W medium dose vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07628049?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07628049's enrollment target sits among peer trials
1,808 3rd of 2000 higher than 1,998 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI